

FORM PTO-1390
REV. 2/01T

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

08698.0001

U.S. APPLICATION NO.
(If known, see 37CFR1.5)

10/019775

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/EP00/06282

July 5, 2000

July 6, 1999

TITLE OF INVENTION

AGENT FOR OCCLUDING BLOOD VESSELS

APPLICANT(S) FOR DO/EO/US


Peter STERK

Applicant(s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed with the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154 (d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ Information Disclosure Statement under 37 CFR 1.97 and 1.98
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A Substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154 (d)(4).
19. ☐ A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).
20. ☒ Other items or information:
 - a. ☒ Copy of cover page of International Publication No. WO 01/02029
 - b. ☒ Annex (Amended) Sheets (2 sheets)
 - c. ☐

U.S. APPLICATION NO. (If known, see 37CFR 1.5) 10/019775		INTERNATIONAL APPLICATION NO. PCT/EP00/06282		ATTORNEY'S DOCKET NUMBER 08698.0001	
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):					
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$1040.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$890.00	
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$740.00	
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$710.00	
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33 (1)-(4)				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	2	- 20 =	x \$18.00	\$	
Independent Claims	1	- 3 =	x \$84.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$	
TOTAL OF THE ABOVE CALCULATIONS =				\$890.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$445.00	
SUBTOTAL =				\$445.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$	
TOTAL NATIONAL FEE =				445.00	
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property. +				\$	
TOTAL FEES ENCLOSED =				\$445.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>\$445.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-0916</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 1300 I Street, N.W. Washington, D.C. 20005-3315					
 SIGNATURE Ernest F. Chapman/25,961					
NAME/REGISTRATION NO.					
DATED: January 4, 2002					

09/019775

Agent for the Occlusion of Blood Vessels

The object of the invention is an agent for the occlusion of blood vessels, which significantly improves the success of surgical procedures, especially of surgical procedures for the removal of carcinoma.

In a method for the embolization of blood vessels already known from European patent application 0 797 988, an anti-angiogenic preparation is introduced into a blood vessel that feeds the tumor to treat carcinoma. The blood supply from the diseased tissue to the healthy tissue and vice-versa is interrupted by the "embolization" of the blood vessel.

It has furthermore already been proposed in DE-OS 197 31 741 to use specific conjugates that comprise a compound capable of fluorescence and a carrier to distinguish between healthy and diseased tissue.

Fibrin glues have also proven useful as agents for the occlusion of vessels. However, the use of conventional fibrin glue in oncology surgery has the disadvantage that so far, it has been very difficult or impossible to distinguish between the diseased tissue to be removed and the healthy issue.

The present invention is therefore based on the problem to provide a suitable agent for the occlusion of blood vessels, which allows a safe distinction between healthy and diseased tissue and can therefore be used

20240526001

advantageously during the surgical removal of the diseased tissue.

The object of the invention is attained with an agent for the occlusion of blood vessels comprising at least two components, i.e., an agent to effect an occlusion of the vessel and a physiologically safe dye. Especially preferred is an agent that comprises a liquid fibrinogen solution to effect the occlusion of the vessel and can be used in cooperation with a liquid thrombin preparation.

The physiologically safe dye is added to one of the two preparations, generally to the thrombin preparation.

The use of the agent in accordance with the invention results in the advantage that it is possible not only to occlude the individual blood vessels, but to stain them as well and thus render the blood- or lymphatic supply visible. The agent can occlude and stain venous as well as arterial blood vessels, and it can also be used in lymphatic vessels.

With the agent in accordance with the invention, it is furthermore possible to visibly separate healthy tissue from diseased tissue. Because each tissue is supplied by a specific artery and vein and by a specific lymph tract, it may be cut off from the blood supply when the appropriate supplying or evacuating supply tract is embolized. Doing this, it is irrelevant what tissue tract is embolized. It is only important that the blood supply to the diseased tissue is interrupted, which can be achieved with the embolization of the arterial as well as the venous

20211015 15:04:20

tissue tracts. Thus, during surgical procedures, the use of the agent in accordance with the invention leads to an occlusion of the vessels that supply the operating area.

For the surgeon, the surgical procedure is significantly simplified by the use of the agent in accordance with the invention because he can now readily distinguish between the diseased and the healthy tissue during the surgery, and can retain as much as possible of the healthy tissue when removing the diseased tissue.

Another advantage of the described agent is that it prevents a diffusion of pathogenic bacteria or body cells into the healthy body tissue because of the occlusion of the blood vessels that supply the operating area. Bacteria, viruses, and tumor cells in particular are therefore fixated in the diseased tissue. The same advantages are obtained when the diseased tissue is infested with parasites, in which case the connection between the healthy tissue and the diseased tissue is also interrupted.

The fibrin glue usable in accordance with the invention is preferably comprised of a stabilized, liquid fibrinogen- and a liquid thrombin preparation. One or both of these preparations should contain a physiologically safe dye that clearly stains the embolized blood vessels. Examples of suitable dyes are methylene blue, quinoline yellow, patent blue, tolonium chloride, indocyanine green and foodstuff- as well as fluorescence dyes.

In addition to this, the tissue glue can contain an added preparation containing the blood coagulation factor XIII,

20210526T001

and thus be used as a three-component-glue. It is also possible, however, to mix the blood coagulation factor XIII into the fibrinogen preparation from the beginning, thus making it a two-component glue. In the case of a three-component glue, the mixing ratio of the fibrinogen, Factor XIII and thrombin components can be appropriately chosen to obtain good mechanical properties of the glue. Suitable mixing ratios, for example, are 1:1:1 and approximately 2:1:1 to approximately 10:1:1.

The tissue glue used in accordance with the invention contains a chaotropic substance in the fibrinogen preparation. Primarily arginine, guanidine, citrulline, urea or its derivatives or mixtures thereof have been shown to be suitable chaotropic substances. They are generally added to the fibrinogen preparation in quantities of 0.1 to 1.0 mol per liter, preferably in quantities of less than 0.5 mol per liter.

The properties of the aforementioned new tissue glues are furthermore advantageously influenced by the addition of an antifibrinolytic. Aprotinine, ϵ -amino caproic acid (EACA), p-amino methyl benzoic acid (PAMBA) or one of their physiologically safe salts or derivatives are primarily used as antifibrinolytic.

Furthermore, the fibrinogen preparation can comprise

- an inorganic salt or

1004975.04.202

- one or more physiologically safe salts of organic carboxylic acids, especially citric acid or lactic acid, or
- one or more amino acids or
- a mono- or disaccharide or
- a sugar alcohol

or one of the mixtures thereof as stabilizers.

The Factor VIII-preparation added to the tissue glue to be used in accordance with the invention must also be stabilized if it is not added to already stabilized fibrinogen. In that case, it is advantageous to add a physiologically safe salt of an organic di-, tri- or tetracarboxylic acid, especially citric acid, and, if necessary, other stabilizers and/or buffer substances for the Factor XIII. Other stabilizers may be

- a mono- or disaccharide or a sugar alcohol and/or
- an amino acid from the group of the glycine, glycylglycine, alanine, cysteine, histidine, glutamine or a physiologically safe salt of the glutamine- or aspartic acid and/or
- a reducing or anti-oxidation agent and/or
- a surface-active substance.

20210326T001

They are generally added to the Factor XIII-preparation in a quantity of up to 5 percent-by-weight. Tissue glues of this type are described in the German patent applications DE-A-198 53 033 and DE-A-198 61 158.

In addition to the aforementioned tissue glue, it is also possible to use other known agents to effect an occlusion of vessels, such as, for example, histoacryl glues. Said glues are liquid agents based on acrylate, which are suitable to be injected into the blood vessels under high pressure and then evenly distribute in the tissue in the liquid phase and harden there.

The invention is explained in more detail by means of the examples.

Shown are:

- Fig. 1 the representation of two ampoules with various content substances,
- Fig. 2 the ampoules in accordance with Fig. 1, with the addition of further additives;
- Fig. 3 the application of the agent in a first embodiment;
- Fig. 4 the application of the agent in a second embodiment, and;
- Fig. 5 the explanation of the effect of the agent in the

202405261001

tissue.

Fig. 1 shows two ampoules 1 and 2 that can be designed in various forms. The ampoule 1 can contain a thrombin solution 2, with a physiologically safe dye being dissolved in connection with thrombin in said bottle. The invention is not limited to this; the ampoule 1 may also contain only a dye solution. The thrombin is added only to improve blood coagulation, but is not absolutely necessary for the agent in accordance with the invention.

The ampoule 3 contains a solution of fibrinogen. The fibrinogen is present in a semi-fluid, highly viscous solution.

To prepare the agent in accordance with the invention, an additive 5, which is preferably comprised of a CaCl_2 -solution for the later hardening of the agent in the tissue, is placed into the ampoule 1.

An aprotinine solution is placed into the second ampoule 3 as additive 6. A mixing ratio of 1:1 of the aprotinine solution and the fibrinogen solution is preferred.

The additive 6 (aprotinine solution) for the fibrinogen is required to start the desired later coagulation chain.

At first, the content substances of the ampoules 1 and 3 do not react with each other.

A reaction takes place only after, according to Fig. 3, the contents of the two ampoules 1 and 3 are drawn into the

202405161001

assigned syringes 1' and 3' and they are connected with one another by a Y-connector according to Fig. 3, as soon as the contents of the two syringes 1' and 3' is injected into the tissue through the Y-connector 7 and a cannula 8.

Fig. 4 shows as another embodiment a combination vessel 9, which contains the components of the two ampoules 1 and 3 in the embodiment according to Fig. 2.

In the upper part, it can contain the contents of the ampoule 3, while the content substances of the ampoule 1 are in the lower part of the combination vessel 9. The two components are separated by a center membrane 10.

A combination vessel of this type is used in a way that the center, separating membrane 10 is destroyed and the combination vessel is then shaken in such a way that all components are mixed. The agent prepared in this way can then be injected into the issue through the opening 19 and an appropriate cannula 8.

Instead of a horizontal membrane, it is also possible that several horizontal membranes or one or more vertical membranes may be present in the combination vessel 9.

Fig. 5 shows an example of the application of the agent on a rectum 11. However, the application of the agent is not limited to a rectum; it is also possible to treat living as well as dead tissues in human and animal bodies with the agent in accordance with the invention.

1001975.041202

Fig. 5 shows that at position 15, for example, i.e., far away of the diseased tissue, the agent from the cannula 8 is injected into a vein 14 under pressure so that it flows into the direction of the arrow 16 and against the direction of the blood flow in the vein 14.

This stains and simultaneously closes all venous tracts (venules 17) in the affected, diseased tissue 12 and creates the possibility to separate the tissue 12 from the adjacent tissue that is not being supplied by the vein 14. Thus, the adjacent tissue is separated from the diseased tissue 12 by a tissue border 18 and is easily distinguishable. In this way, the diseased tissue 12 can be removed from the adjacent, healthy tissue by a simple, optical control during the surgery.

Another essential advantage of the agent in accordance with the invention is that the diseased tissue has, at least in the border area, closed vessels in which bacteria are immobilized and fixated and thus cannot enter into healthy, not yet diseased tissue.

However, the agent in accordance with the invention can also be injected into an artery 13, and can then also enter the arterial tracts of the tissue 12 in the direction of the arrow 16, where it closes the arterial tracts there permanently while simultaneously staining them.

It is therefore important for the present invention that the agent is comprised of at least two components, i.e., a substance that is suitable for effecting an embolization of

2001-05-04 10:42:00

the tissue, and also a dye that is suitable to stain the appropriate occluded tissue during the occlusion.

20240515.04202

List of reference symbols:

- 1 Ampoule
- 2 Filling (colorant solution with or without thrombin)
- 3 Ampoule
- 4 Filling (fibrinogen)
- 5 Additive (CaCl_2)
- 6 Additive (aprotinine solution)
- 7 Y-connector
- 8 Cannula
- 9 Combination vessel
- 10 Membrane
- 11 Rectum
- 12 Tissue
- 13 Artery
- 14 Vein
- 15 Position
- 16 Direction of arrow
- 17 Venules
- 18 Tissue border
- 19 Opening
- 20 Lymph tract

202410 5 26 1001

Patent Claims

1. Agent for the occlusion of blood vessels, characterized in that it comprises at least two components, i.e., an agent to effect the occlusion of a vessel and a physiologically safe dye.
2. Agent in accordance with claim 1, characterized in that the agent for effecting the occlusion of the vessel comprises a liquid fibrinogen preparation, which can also contain an added liquid thrombin preparation.
3. Agent in accordance with claims 1 and 2, characterized in that it comprises a dye selected from the group methylene blue, quinoline yellow, patent blue, tolonium chloride, indocyanine green as well as from the foodstuff- and fluorescence dyes.
4. Agent in accordance with claim 1, characterized in that the agent for effecting the occlusion of a vessel comprises a histoacryl glue.

2025-04-20 10:40:40

1/2





FIG. 1





FIG. 2




FIG. 3

202110-5865001

2/2




FIG. 4




FIG. 5

202140-5/26T00T

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: AGENT FOR OCCLUDING BLOOD

VESSES the specification of which ☐ is attached and/or ☒ was filed on JANUARY 4, 2002 as United States Application Serial No. _____ or PCT International Application No. _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT International application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C.
GERMANY	299 11 689.1	JULY 6, 1999	<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)

I hereby appoint the following attorney and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected herewith: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 6,691; G. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 0,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilly, Reg. No. 7,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Living, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewis, Reg. No. 28,818; Martin Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard J. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; Roger D. Taylor, Reg. No. 28,922; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 2,013; Andrew Chanhon Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neth, Reg. No. 36,363; Gerson S. Panitch, Reg. No. 33,751; Cheri M. Taylor, Reg. No. 3,216; Charles E. Van Horn, Reg. No. 40,266; Linda A. Wadler, Reg. No. 33,218; Jeffrey A. Berkowitz, Reg. No. 36,743; Michael R. Kelly, Reg. No. 3,921; James B. Monroe, Reg. No. 33,971; Doris Johnson Hines, Reg. No. 34,629; Allen R. Jensen, Reg. No. 28,224; Lori Ann Johnson, Reg. No. 34,498; and David A. Manspelzer, Reg. No. 37,540 and _____ Please address all correspondence to FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P. 1300 I Street, N.W., Washington, D.C. 20005, Telephone No. (202) 408-4000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor <u>Dr. Peter J.W. Stahl</u>	Inventor's Signature <u>[Signature]</u>	Date <u>04.03.02</u>
Residence <u>Hamburge Str. 55 b</u>	Citizenship <u>Germany</u> DEX	
Post Office Address <u>23558 Lübeck</u>		